Pernix Therapeutics Patient Assistance Program. (PTX is helps people in need)
At Pernix Therapeutics, we believe that a lack of prescription insurance coverage and cost should not prevent patients from getting the medication they need. To make sure patients have access to the medications prescribed by their healthcare providers, Pernix Therapeutics is proud to offer the Pernix Therapeutics Patient Assistance Program. The Pernix Therapeutics Patient Assistance Program delivers Pernix Therapeutics selected medications at no cost to eligible patients.
TREND IS YOUR FRIEND WHEN YOU LOOK AT THE MARKET IS THERE A WIND AT YOUR BACK ? BE CAREFUL…EVEN TURKEYS CAN FLY IN A TORNADO… That's what happened in the market. To many Drug stocks ( many without revenue and positive earnings) became over rated along with many other sectors. Just like Housing/gold & oil/gas related socks. What sectors will be the next to rise or fall?
PTX does have earnings and new product growth. They are accumulating products at a cost. As their products bring in new value and revenues, PTX will see higher earnings/revenue/cash. PTX finds great deals and will continue to add more products/partners to their portfolio over time. They are also ripe for another company to buy them as they expand their products. It depends what direction they are going. Growth or Growth for buyout at much higher price.
As they say, "Trend is Your Friend"! Now find the pattern. High MA Failing in making new Highs, and Low MA making new Lows, Warns of a Trend Change......Already happened! Now we recently had, Low MA making New Lows (Bottoms) and High MA making New Highs...Warns of a Trend Change.....
So if you did not cover or buy at the bottom. $1.91, you most likely missed your best price to cover or buy...
Do NOTE that PTX's revenue trends for 2016/2017 will more than triple.....
Why because you say so? Price has already hit and bounced off a price lower than it should have gone...Greed is where you are....and that is Pathetic....
Hope you covered or went long yesterday...since Hillary's outlined drug plans have a low or little chance of success....Her remarks was just a good excuse to put a negative outlook on all drug stocks and put a scare into selling created by again, the news media. Of course the shorts picked this up and took advantage knowing this sector has been overheated for awhile.
Most drug Stocks are now appear to be oversold and have little or nowhere to go but up....
Presidential candidate Hillary Clinton outlined her plans to curtail rising drug prices. We believe her proposals have been suggested in the past by others, with limited impact on the industry. Clinton's call for Medicare to negotiate drug pricing has been suggested in the past and we see little chance of this passing a Republican controlled Congress. Clinton also calls for a $3K annual cap on out-of-pocket spend for drugs, but healthcare reform already includes a cap. Also, a R&D spending mandate will have limited impact on biotech names such as Celgene (CELG 115
The $600 billion advertising industry, which is growing at 5% rate annually, is undergoing a rapid transition. While TV ads continue to rule the roost with over 40% share, digital ads that include online desktop and mobile ads have taken the center stage and are growing at a rapid pace. According to eMarketer, Mobile advertising is the key driver of growth around the world and advertisers will spend $64.25 billion worldwide on mobile advertising in 2015, an increase of nearly 60% over 2014. So while social media platforms, search engines, programmatic ad platforms and other Internet properties stand to gain from this trend, the clear losers are the TV networks and print media that rely on advertising.
Budget allocation for online ads is increasing at the expense of TV and print media. While budget for TV ads is expected to shrink by 3% each year till 2020, print ad revenue is on a steep decline. World-wide, print ads declined 5.2% in 2014 from a year earlier and are down over 17.5% over the last five years. This leads us to believe that print ads will be relegated to the botoom tier and makeup only a small portion of the ad industry in the future. However, a turf war between TV ads and Online ads will continue in the near foreseeable future.
What Is Driving The Fundamental Shift In Ad Dollars From Traditional To Online Media?
The Internet advertising market is gaining traction owing to increasing ubiquity of smartphones, tablets and PCs, coupled with an improvement in ad measurement techniques. Internet penetration is changing user behavior and user-generated content is facilitating a move away from traditional content generation sources such as TV and printpublications. More notably, the move online is being driven by the emergence ofprogrammatic platforms that is enable advertisers to generate higher ROI for their ad dollars by matching relevant ads to websites with engaging content across geographies and time slots. Consider the following:
Sentiment: Strong Buy
This Week Could get a little Bumpy for Biotech, as Hillary moves forward with her newest Presidential campaign approach! Can her plans work? She could not get the Health Care Plan Right when she was in charge in revamping Healthcare during President Clinton term. OBAMA took office and created his own Health Care Plan in less time than Hillary could say Here's My New Health Care Plan....
Hillary's Newest Proposals:
Drug price plan could be a part of a group of health proposals from Clinton, who said Sunday on the television program "Face the Nation" that she had several ideas on health care.
"I’m going to address them this week, starting with how we’re going to try to control the cost of skyrocketing prescription drugs," she said. "It’s something that I hear about wherever I go."
The index was already vulnerable and Clinton’s tweet was likely a major factor in the decline, said John Fraunces, portfolio manager of Turner Medical Sciences Fund, said by phone. "Pricing is a theme that seems to be of growing concern in health care area, ourselves included."
Terry Haines, a political analyst with Evercore ISI, didn’t think Clinton could actually have an impact. "Regardless of what any Democratic candidate says about drug pricing, his or her ability to make that a reality as president is close to zero." Haines said in a note to clients that he doubted a drug pricing proposal could get through Congress.
Clinton's Tweet on High Drug Prices Sends Biotech Stocks Downs. Hillary Clinton tweeted Monday that she would release a plan to combat the high cost of prescription drugs.
And of course you bashers deserve to be here bickering and trying to find fault in everything about PPHM. But noticed you do not give any credit where credit is deserved....Lots of progress and new pipeline growth to continue thru end of 2015 and beyond.
Note: PPHM is now collaborating with several companies. and expanding their future pipeline with revenues they earn with their growing manufacturing plant...........
1. Peregrine and AstraZeneca Collaborate Immuno-Oncology Combination Clinical Trial--evaluate bavituximab in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736) in multiple solid tumors.
Collaboration with Memorial Sloan Kettering Cancer Center to evaluate combinations of bavituximab with other checkpoint inhibitors and immune stimulatory agents for the purpose of developing new and increasingly effective anti-cancer treatments.
2. Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015--
3. Avid Bioservices Reports $9.4 Million in **First Quarter Revenue** (1 quarter Rev.) Higher future quarters will pay for Sunrise Phase III Trial..
4. Peregrine announced plans to expand the bavituximab clinical development program to include a Phase II trial to evaluate the combination of bavituximab and Opdivo(R) (nivolumab), an anti-PD-1 antibody, in previously treated, metastatic NSCLC. This trial is expected to be initiated by the end of calendar year 2015.
-- Peregrine announced plans to expand the bavituximab clinical development program to include a Phase II/III trial to evaluate bavituximab with chemotherapy combinations in HER2-negative metastatic breast cancer. This trial is expected to be initiated by the end of calendar year 2015.
5. New key positive findings from several recent bavituximab-focused studies.
6. Avid Bioservices Highlights: -- Avid's new manufacturing suite is fully constructed. Company plans to announce the launch.
Contract manufacturing committed backlog reached $42 million from existing customers covering services to be completed in FY 2016 and into FY 2017.
7. Corporate Highlights
-- The European Patent Office (EPO) granted Patent Number 2,269,656, licensed to Peregrine titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer." The patent covers bavituximab as a composition of matter and for use in therapy, such as for treating cancer including in combination with radiotherapy or chemotherapy, e.g., with docetaxel. This important patent expands upon the company's intellectual property portfolio, which now numbers more than 140 worldwide issued patents and pending applications for the bavituximab oncology program.
8. Peregrine expects third-party contract manufacturing revenue for FY 2016 to be between $30 and $35 million. In addition to providing biomanufacturing services to its third-party clients, Avid will continue to support the clinical and potential commercialization of bavituximab.
9. Peregrine reported $59,016,000 in cash and cash equivalents as of July 31, 2015 compared to $68,001,000 at fiscal year ended April 30, 2015. (That’s only $11 mil less cash used. PPHM revenues FY 2016 were $9,379,000 vs expense/cost of $23,425,000 for FY 2016).
Eventually all that continued complaining about PPHM is not going to do much for your egos in the future, as PPHM continues moving forward and continues showing new positive proof and new product developments.
Jul 13, 2015 - Brean Capital Positive on Ohr Pharmaceutical (OHRP) Squalamine; Sees 1400% Upside
Sentiment: Strong Buy
brokerage presently has a $13.00 price on the stock. Craig Hallum’s target price suggests a potential upside of 41.30%
Cash and cash equivalents at end of period $210,035! Total stockholders’ equity 2015 $283,103
2014 $276,888. Total revenue increased to $55.9 million compared to $51.7 million a year ago.
-- Revenue from media and advertising increased 14% compared to a year ago.
-- Adjusted EBITDA was $4.6 million compared to $3.7 million a year ago.
GAAP net loss for the second quarter 2015 was $9.3 million, which included $8.5 million in stock-based compensation expense and $2.1 million in change in fair value of contingent consideration expense related to our acquisition of Eckim. GAAP net loss in the second quarter of 2014 was $6.9 million, which included $6.7 million in stock-based compensation expense.
-- Cash generated from operations was $6.9 million compared to $5.2 million in the same period last year.
-- Total digital coupon transactions during the second quarter were 372 million compared to 384 million in second quarter 2014.
Digital coupon transaction volumes through Retailer iQ increased almost 70% in the first half of 2015 as compared to the second half of 2014.
Growth in media:
-- Our media and advertising business grew 14% year over year
Looks like you need to sell your garbage. In reality, company did better than 2014 and meet their revenues. Revenues to grow 2015 along with new business/products/ads/coupons/retailers etc.. Coup stock moved from $14 to $9 following sector underperformance. Looks like Coup has overly paid for its peers.....
I'd say time to buy when the sector in down....as overdone.... Looks like you need to sell your garbage.
Last quarterly expecting positive forward.....Coup is in sector that was hit with negative earnings from SALE and Twtr etc. Coup meets or surprise, they will be fine. This follow the sector thing is way over done in my view....Sale down 38% today....Coup has a different business and is expanding it forward....
Sentiment: Strong Buy
PTX: Yes A Poison Pill Could Be a Reason for new shares or are possibly being used in buying/adding a lot more new products to their pipelines, or both. In a securities filing, Depomed said it has adopted a poison-pill plan that would be triggered by a person or group acquiring a more than 10% stake in the company. A poison pill, or shareholder rights plan, is designed to dilute the value of stock by flooding the market with additional shares, making it more difficult for an investor to acquire a controlling stake.
Terms of the agreement (PTX NEW SHARES related to Merger ) NOTE Milestones PTX To Receive!
Under terms of the agreement (as amended), Pernix, through its wholly-owned subsidiary, Ferrimill Limited (“Ferrimill”), has paid Zogenix $70 million in cash, issued to Zogenix 1,682,086 shares of Pernix common stock and deposited an additional $10 million in cash in escrow to fund potential indemnification claims for a period of 12 months following the closing. Pernix has also purchased certain Zohydro ER inventory as part of the transaction.
Ferrimill has also agreed to make certain payments conditioned on regulatory and commercial milestones of up to $283.5 million, including $12.5 million upon approval of ZX-007, a tablet formulation of extended-release hydrocodone with abuse-deterrent properties, and up to $271 million in potential sales milestones based on the achievement of pre-determined annual product sales milestones for Zohydro ER and ZX-007. Under the terms of the acquisition agreement, over 80% of the value of the sales milestones is tied to the achievement of net sales targets ranging from $500 million to $1 billion.
Pernix will purchase a pre-defined amount of Zohydro ER product inventory. Pernix will also seek to retain certain employees of Zogenix, including the field sales force of approximately 100 sales professionals and additional personnel related to the brand.
Jefferies LLC acted as financial advisor to Pernix. The Company’s legal advisers are Lowenstein Sandler LLP and Goodwin Procter LLP. Buchanan Ingersoll & Rooney PC acted as intellectual property counsel.
Who's to know what management has planned. Shares could be used for future mergers?
It's called investing for future growth. If the company makes new income from their new purchase, that puts PTX in a positive growth and those extra shares will/could mean future higher income/stock price and so on.
Look how many outstanding shares other companies have compare to PTX'S 43 M shares. CELG 800 Mil, AMRN 176 M, AMGN 760 M, GILD 1.5 B outstanding shares, etc.. It's all about expanding growing their business. New management has managed to do so in a short time compared to old management.
Look on the bright side, one can buy these shares while they are cheap...The street has turned itself into a manipulative stock market. Wish we had the old stock market days back before the computer and all the naked shorting. While Bubbles and Recessions have always be around. ...As... they... say, "Don't put all your eggs in one basket"! Having your home and debt paid off is the best investment you can ever make. Stock market should just be considered gambling and risky in this worlds economy. One should only use a small percentage of your savings for stock investing.
Pernix Therapeutics Inc. to Report Second Quarter 2015 Financial Results On Thursday, August 6, 201
nvaa2, thanks for the welcome. So many mouthy shorts getting hyper as OHR shows it's true colors and analyst are taking a positive look. Invest in several drug companies and try to keep up on the news and new products. When the street missed OHR'S positive information in May, had to buy. Must be those Wall Street Games they play.
My opinion from research, Could OHR be used exclusively for some eye conditions without lucentis or any other injectable.
Lucentis is administered in the form of smaller molecules in its ability to penetrate the eye's retina and halt abnormal blood vessel growth contributing to advanced macular degeneration and scarring that causes blindness.
“So can OHR’S own formulated drops stop abnormal blood vessel growth and also become a healing drug that works on bringing back the normal vessels?” Having the recent positive vision improvements, is showing us that adding the drops are absorbing faster than just using lucentis alone. Adjusting the dosage higher or lower will come in time once they can demonstrate through a phase III trial.”
The main challenge will be to demonstrate Squalamine's ability to travel to the back of the eye and stay there long enough to be absorbed. "Complete replacement (for injections) is completely unnecessary for Ohr's success," said Aschoff. "Just look at how well Eylea is doing with reduction of injection frequency as its main thrust." Like Eylea a and Lucentis, Squalamine targets a specific protein, VEGF, or vascular endothelial
growth factor, in order to block the formation and growth of new blood vessels in the eye. It also targets other factors behind blood vessel growth.
Analyst from 2013 If the results are good, Aschoff said it might eventually make sense for Ohr, which is also developing a treatment for cancer cachexia, a severe wasting disorder, to sell itself or Squalamine to a bigger competitor. "(The acquirer) could buy it to sit on it, and not develop it, to save their injectable franchise," he said. "Or they could buy it to develop it - and see whichever one brings in the most revenue."
Sentiment: Strong Buy
Type Phase III Trials in wet-AMD 11-May-2015 Quarterly Report
The data from the Phase II clinical trial support the Company conducting Phase III trials for a targeted population, with enrollment criteria to be determined based on a complete analysis of the Phase II clinical trial.
The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the end of the study, supporting the planned Phase III development program for a targeted population.
At an end of Phase II meeting with the U.S. Food and Drug Administration ("FDA") in September 2014, the FDA agreed with the Company on a 9 month primary efficacy endpoint for the Phase III trials. We anticipate initiating the Phase III clinical trial program in the second half of calendar 2015.
Sentiment: Strong Buy
So why would FDA approve a phase III trial if Failed? Prove to me where OHRP stated that 1st phase 2 trial Failed? Appears that fewer injections did not happen but everything else proved to be positive.
Improved vision vs fewer injections.
Street made a huge error selling down OHRP stock on injections alone, not viewing positive Vision response.
CEO 1st phase 2 statement...
Ohr Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference
Visual Acuity Benefits Demonstrated in Classic CNV Containing Lesions
Data Support a Phase III Development Program in an Optimized Wet-AMD Patient Population
"The results from the IMPACT study demonstrate that topically administered OHR-102 combination therapy can lead to improved visual function in patients with wet AMD and, importantly, that the efficacy results may be determined by lesion size and composition," stated Dr. Jason Slakter, Chief Medical Officer at Ohr. "There was a clear and clinically meaningful benefit in patients whose lesions contained some classic CNV. These data support a Phase III development program in a targeted population which will be based upon a complete analysis of the IMPACT study results. We expect to commence the Phase III development program with OHR-102 combination therapy in the second half of 2015."
Dr. Slakter also presented the data on patients with classic containing lesions in the intent-to-treat (ITT-LOCF) population (OHR-102 n=38, Lucentis monotherapy n=32). In this group, the mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. In addition, 42% of the patients receiving OHR-102 achieved a ≥3 line gain at nine months, as compared to 28% in the Lucentis monotherapy group.
As previously reported, the mean number of injections between the treatment arms over the 9 months of treatment, the primary endpoint of the study, was not meaningfully different.
Sentiment: Strong Buy